Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Dec;8(23):1614.
doi: 10.21037/atm-2020-115.

Camrelizumab-targeting a novel PD-1 epitope to treat hepatocellular carcinoma

Yannick Sebastiaan Rakké  1 , Dave Sprengers  2 , Jaap Kwekkeboom  2 , Jan Nicolaas Maria IJzermans  1
Affiliations
Editorial

Camrelizumab-targeting a novel PD-1 epitope to treat hepatocellular carcinoma

Yannick Sebastiaan Rakké et al. Ann Transl Med. 2020 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure from (available at http://dx.doi.org/10.21037/atm-2020-115). The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Tumour cell and CD8 T cell interaction. HCC harbours an immunosuppressive tumour microenvironment (TME). Compared to tumour-free (TF) surrounding liver tissues, intratumoural immune infiltrates have increased proportions of immunosuppressive regulatory T cells (Tregs) and decreased proportions of proinflammatory natural killer (NK-), NKT, and cytotoxic CD8+ T cells (4). PD-1 is upregulated on tumour-infiltrating helper and CD8+ T cells (5). Tumour cells and tumour-infiltrating myeloid cells express PD-1-Ligand (PDL-1) and suppress T cell functionality via downstream inhibition of T cell receptor (TCR) and costimulatory (B7-1/-2–CD28) signalling through the interaction of PDL-1 with PD-1. Immunosuppression via PD-1 is abrogated by anti-PD-1 blocking antibodies (e.g., nivolumab, pembrolizumab, camrelizumab), that prevent PD-1/PDL-1 ligation, restoring CD8+ T cell-mediated antitumour immune responses.
See this image and copyright information in PMC

Comment on

References

    1. Ferlay J, Ervik M, Lam F, et al. Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. 2018. Available online: https://gco.iarc.fr/today, accessed 11-05-2020.
    1. McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of hepatocellular carcinoma. Hepatology 2020. doi: .10.1002/hep.31288 - DOI - PMC - PubMed
    1. Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet 2018;391:1301-14. 10.1016/S0140-6736(18)30010-2 - DOI - PubMed
    1. Pedroza-Gonzalez A, Verhoef C, IJzermans JNM, et al. Activated tumor-infiltrating CD4+ regulatory T cells restrain antitumor immunity in patients with primary or metastatic liver cancer. Hepatology 2013;57:183-94. 10.1002/hep.26013 - DOI - PubMed
    1. Zhou G, Sprengers D, Boor PPC, et al. Antibodies against immune checkpoint molecules restore functions of tumor-infiltrating t cells in hepatocellular carcinomas. Gastroenterology 2017;153:1107-1119.e10. 10.1053/j.gastro.2017.06.017 - DOI - PubMed